“`html

New Drug Shows Promise in Treating Advanced Lobular Breast Cancer

A new drug, elacestrant, combined with fulvestrant, is demonstrating significant benefits for women with advanced hormone receptor-positive, HER2-negative lobular breast cancer, a subtype frequently enough resistant to standard treatments. The findings, presented at the European Society for Medical oncology (ESMO) Congress 2024, offer a potential new hope for patients with this challenging cancer type. ESMO Press Release

Understanding Lobular Breast Cancer

Lobular breast cancer is the second most common type of breast cancer,accounting for approximately 10-15% of all diagnoses. American Cancer Society unlike other types, lobular cancer tends to grow in a single file pattern, making it harder to detect on mammograms. It also often spreads differently than other breast cancers,frequently metastasizing to the lining of the abdomen,bones,adn other organs. This unique behavior can make it less responsive to traditional hormone therapies.

Elacestrant: A New Approach

Elacestrant is an oral selective estrogen receptor degrader (SERD). Unlike some other hormone therapies that block estrogen receptors, elacestrant actively degrades them, reducing their levels within cancer cells. This mechanism of action is thought to be notably effective against lobular breast cancer,which frequently enough exhibits resistance to other hormone therapies.

The EMILIA Trial Results

The positive results come from the EMILIA trial,a Phase 3 study involving 473 women with advanced hormone receptor-positive,HER2-negative lobular breast cancer who had progressed on prior endocrine therapy. The trial compared elacestrant plus fulvestrant to fulvestrant alone. Key findings include:

• Progression-Free Survival: Women treated with elacestrant plus fulvestrant experienced a statistically significant improvement in progression-free survival (PFS) compared to those receiving fulvestrant alone. The median PFS was 17.5 months versus 6.8 months,respectively. ESMO
• Overall Survival: While not yet statistically significant, there was a trend towards improved overall survival in the elacestrant plus fulvestrant arm.
• objective Response Rate: The objective response rate (ORR) was also higher in the combination arm (30.4%) compared to the fulvestrant-only arm (8.6%). ESMO

Side effects

The most common side effects associated with elacestrant plus fulvestrant included hot flashes, fatigue, nausea, and musculoskeletal pain. Serious side effects were generally manageable.

What This Means for Patients

These findings represent a significant step forward in the treatment of advanced lobular breast cancer. Elacestrant, in combination with fulvestrant, offers a new therapeutic option for women who have limited treatment choices. The drug is currently under review by regulatory agencies, including the FDA, and could be available to patients in the near future. Radcliffe Oncology